JP2017532365A5 - - Google Patents

Info

Publication number

JP2017532365A5

JP2017532365A5 JP2017525311A JP2017525311A JP2017532365A5 JP 2017532365 A5 JP2017532365 A5 JP 2017532365A5 JP 2017525311 A JP2017525311 A JP 2017525311A JP 2017525311 A JP2017525311 A JP 2017525311A JP 2017532365 A5 JP2017532365 A5 JP 2017532365A5

Authority

JP

Japan

Prior art keywords

collagen

pharmaceutical composition

chain polypeptide

protein

amino acid

Prior art date

2015-07-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102000008186 Collagen Human genes 0.000 claims 26
• 108010035532 Collagen Proteins 0.000 claims 26
• 229920001436 collagen Polymers 0.000 claims 26
• 239000008194 pharmaceutical composition Substances 0.000 claims 18
• 229920001184 polypeptide Polymers 0.000 claims 18
• 102000004196 processed proteins & peptides Human genes 0.000 claims 18
• 108090000765 processed proteins & peptides Proteins 0.000 claims 18
• 102000004169 proteins and genes Human genes 0.000 claims 14
• 108090000623 proteins and genes Proteins 0.000 claims 14
• 150000001413 amino acids Chemical group 0.000 claims 12
• 102000002067 Protein Subunits Human genes 0.000 claims 9
• 108010001267 Protein Subunits Proteins 0.000 claims 9
• 208000003215 hereditary nephritis Diseases 0.000 claims 7
• 208000024985 Alport syndrome Diseases 0.000 claims 4
• 210000004027 cell Anatomy 0.000 claims 4
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 4
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 3
• 238000003556 assay Methods 0.000 claims 3
• 239000000539 dimer Substances 0.000 claims 3
• 208000006750 hematuria Diseases 0.000 claims 3
• 238000004519 manufacturing process Methods 0.000 claims 3
• 201000001474 proteinuria Diseases 0.000 claims 3
• BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 claims 3
• BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 208000025760 Benign familial haematuria Diseases 0.000 claims 2
• 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
• 208000032843 Hemorrhage Diseases 0.000 claims 2
• 230000005856 abnormality Effects 0.000 claims 2
• 230000000740 bleeding effect Effects 0.000 claims 2
• 208000020832 chronic kidney disease Diseases 0.000 claims 2
• 230000007812 deficiency Effects 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 201000000523 end stage renal failure Diseases 0.000 claims 2
• 210000000585 glomerular basement membrane Anatomy 0.000 claims 2
• 229960002591 hydroxyproline Drugs 0.000 claims 2
• 201000006370 kidney failure Diseases 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• 108010050451 2-oxoglutarate 3-dioxygenase proline Proteins 0.000 claims 1
• 206010002329 Aneurysm Diseases 0.000 claims 1
• 201000002431 Autosomal dominant Alport syndrome Diseases 0.000 claims 1
• 208000014644 Brain disease Diseases 0.000 claims 1
• 208000029812 Cerebral Small Vessel disease Diseases 0.000 claims 1
• 208000032274 Encephalopathy Diseases 0.000 claims 1
• 208000002111 Eye Abnormalities Diseases 0.000 claims 1
• 208000028782 Hereditary disease Diseases 0.000 claims 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
• 239000004472 Lysine Substances 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 1
• 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 1
• 102000018399 Prolyl 3-hydroxylases Human genes 0.000 claims 1
• 108010043005 Prolyl Hydroxylases Proteins 0.000 claims 1
• 102000004079 Prolyl Hydroxylases Human genes 0.000 claims 1
• 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 claims 1
• 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims 1
• 208000001647 Renal Insufficiency Diseases 0.000 claims 1
• 201000002429 X-linked Alport syndrome Diseases 0.000 claims 1
• 239000003963 antioxidant agent Substances 0.000 claims 1
• 201000002430 autosomal recessive Alport syndrome Diseases 0.000 claims 1
• 210000002469 basement membrane Anatomy 0.000 claims 1
• 239000000090 biomarker Substances 0.000 claims 1
• 230000021164 cell adhesion Effects 0.000 claims 1
• 230000024245 cell differentiation Effects 0.000 claims 1
• 230000012292 cell migration Effects 0.000 claims 1
• 230000002490 cerebral effect Effects 0.000 claims 1
• 239000002738 chelating agent Substances 0.000 claims 1
• 230000002950 deficient Effects 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 230000004064 dysfunction Effects 0.000 claims 1
• 208000028208 end stage renal disease Diseases 0.000 claims 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims 1
• 230000001434 glomerular Effects 0.000 claims 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
• 238000007917 intracranial administration Methods 0.000 claims 1
• 238000007918 intramuscular administration Methods 0.000 claims 1
• 238000007912 intraperitoneal administration Methods 0.000 claims 1
• 238000007913 intrathecal administration Methods 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 238000010253 intravenous injection Methods 0.000 claims 1
• 238000007914 intraventricular administration Methods 0.000 claims 1
• 239000007951 isotonicity adjuster Substances 0.000 claims 1
• 230000007774 longterm Effects 0.000 claims 1
• 238000005259 measurement Methods 0.000 claims 1
• 210000003205 muscle Anatomy 0.000 claims 1
• 230000009984 peri-natal effect Effects 0.000 claims 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
• 210000004129 prosencephalon Anatomy 0.000 claims 1
• 238000001525 receptor binding assay Methods 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 208000019553 vascular disease Diseases 0.000 claims 1